RT Journal Article
SR Electronic
T1 Clinical characteristics and epidemiology survey of lung transplantation recipients accepting surgeries during the COVID-19 pandemic : from area near Hubei Province
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.06.20147264
DO 10.1101/2020.07.06.20147264
A1 Qiu, Lingxiao
A1 Chen, Shan shan
A1 Wang, Cong
A1 Liu, Caihong
A1 Wang, Huaqi
A1 Zhao, Xiaoguang
A1 Fang, Zeming
A1 Chang, Siyuan
A1 Zhao, Gaofeng
A1 Zhang, Guojun
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.07.06.20147264.abstract
AB Lung transplantation recipients (LTx) were susceptible to severe acute respiratory syndrome-corona virus-2 (SARS-Cov-2) and suffered a higher mortality risk than healthy subjects. Here we aim to analyze whether it was appropriate or and valuable to maintain lung transplant programs in medical institutions accepting coronavirus disease 2019 (COVID-19) patients. In this study, the clinical characteristics, laboratory testing and epidemiology survey results of 10 LTx recipients undergoing allograft lung transplantation surgeries in the First Affiliated Hospital of Zhengzhou University during the COVID-19 pandemic were collected. A web-based epidemiology questionnaire was used to collect the information of LTx recipients after discharge. Up to now, none of the LTx recipients or their family members get infected with SARS-CoV-2 during the novel coronavirus pandemic. In conclusion, under the premise of taking appropriate preventive measures during hospitalization and after discharge, the lung transplant program can be maintained in the medical institution that accepts patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the New Coronavirus Prevention and Control Emergency Research Project of Henan Province in China (No.201100311000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical review committee of the First Affiliated Hospital of Zhengzhou University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.